Edwards Lifesciences Corp (EW) Shares Sold by Torch Wealth Management LLC

Share on StockTwits

Torch Wealth Management LLC cut its position in Edwards Lifesciences Corp (NYSE:EW) by 37.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,685 shares of the medical research company’s stock after selling 6,345 shares during the period. Torch Wealth Management LLC’s holdings in Edwards Lifesciences were worth $1,860,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the company. LPL Financial LLC boosted its stake in Edwards Lifesciences by 13.1% during the first quarter. LPL Financial LLC now owns 18,607 shares of the medical research company’s stock worth $2,596,000 after buying an additional 2,160 shares during the last quarter. CIBC World Markets Inc. boosted its stake in Edwards Lifesciences by 1,099.7% during the first quarter. CIBC World Markets Inc. now owns 23,395 shares of the medical research company’s stock worth $3,264,000 after buying an additional 21,445 shares during the last quarter. WINTON GROUP Ltd boosted its stake in Edwards Lifesciences by 26.8% during the first quarter. WINTON GROUP Ltd now owns 11,227 shares of the medical research company’s stock worth $1,566,000 after buying an additional 2,373 shares during the last quarter. Principal Financial Group Inc. boosted its stake in Edwards Lifesciences by 5.4% during the first quarter. Principal Financial Group Inc. now owns 461,654 shares of the medical research company’s stock worth $64,409,000 after buying an additional 23,652 shares during the last quarter. Finally, Suntrust Banks Inc. boosted its stake in Edwards Lifesciences by 13.1% during the first quarter. Suntrust Banks Inc. now owns 18,678 shares of the medical research company’s stock worth $2,605,000 after buying an additional 2,168 shares during the last quarter. 82.34% of the stock is currently owned by hedge funds and other institutional investors.

NYSE:EW traded down $1.01 on Tuesday, reaching $148.30. The company’s stock had a trading volume of 159,423 shares, compared to its average volume of 2,377,605. Edwards Lifesciences Corp has a 12-month low of $100.20 and a 12-month high of $175.00. The company has a quick ratio of 1.47, a current ratio of 1.86 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $30.45 billion, a P/E ratio of 39.03, a P/E/G ratio of 2.01 and a beta of 0.56.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 26th. The medical research company reported $1.24 EPS for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The company had revenue of $972.00 million for the quarter, compared to the consensus estimate of $968.32 million. During the same quarter in the previous year, the business earned $1.08 earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. Sell-side analysts anticipate that Edwards Lifesciences Corp will post 4.67 earnings per share for the current fiscal year.

A number of research firms have weighed in on EW. Citigroup boosted their price objective on Edwards Lifesciences from $115.00 to $118.00 and gave the stock a “sell” rating in a research note on Tuesday, July 31st. Zacks Investment Research lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Wednesday, September 19th. Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Finally, Morgan Stanley boosted their price objective on Edwards Lifesciences from $150.00 to $157.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $154.70.

In related news, VP Catherine M. Szyman sold 700 shares of the business’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $142.64, for a total value of $99,848.00. Following the sale, the vice president now owns 27,772 shares in the company, valued at approximately $3,961,398.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Huimin Wang sold 3,800 shares of the business’s stock in a transaction on Friday, October 5th. The shares were sold at an average price of $152.79, for a total value of $580,602.00. Following the completion of the sale, the vice president now owns 81,665 shares in the company, valued at approximately $12,477,595.35. The disclosure for this sale can be found here. Insiders sold 153,211 shares of company stock worth $21,906,185 in the last 90 days. Company insiders own 1.84% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply